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Objective: To evaluate patient perspectives regarding utilization of intravenous (IV) therapy
for inflammatory arthritis (IA).
Methods: This was a single-center, noninterventional, patient questionnaire-based study of
adult IA patients currently receiving IV biologics. At a single visit, patients completed the
questionnaire comprising 30 questions centered on their experience receiving an intravenously
administered therapy to treat their IA. The questionnaire included questions on patient demographics, disease characteristics, and previous biologic treatment for IA (subcutaneous [SC] and
IV). Patients rated their level of agreement with statements regarding satisfaction with current
IV biologic therapy and potential advantages and disadvantages of IV biologic therapy using
a 5-point Likert scale (1= strongly disagree, 5= strongly agree).
Results: One hundred patients were enrolled and completed the survey; 66% were female and
the mean age was 58 years. Before IV treatment, 97% of patients received information regarding therapy options. Ninety patients ranked their satisfaction with current IV therapy as 4 or 5.
The proportion of patients with an “extremely favorable” perception of IV therapy increased
from 33% to 71% following initiation of their current medication. Thirty-one patients had
previously received SC therapies to treat their IA.
Conclusion: These results demonstrated an overall favorable perception of IV therapy among
this patient population. Patients previously treated with SC therapy also had a positive shift in
the perception of IV therapy after initiating IV therapy. Patients’ perception and preference for
treatment options should be highly considered by the treating physician during or as part of a
shared decision-making process.
Keywords: intravenous, patient satisfaction, arthritis, biologic therapy
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Currently, biologic agents for treating inflammatory arthritis (IA) are administered
either as subcutaneous (SC) injections or intravenous (IV) infusions. Given the variety
of biologic therapies available for patients with IA, patient preferences regarding the
mode of administration may play an important role in treatment adherence.1 Factors
that may influence patient preferences for SC or IV treatment include how the drug
is administered (ie, self-administered at home vs traveling to a health-care setting),
medication storage requirements, and frequency of dosing. Among patients receiving
either SC or IV antitumor necrosis factor (TNF) therapy, individual patient preference was reported as fundamental to the selection of a therapeutic agent and route
of administration, both of which increased treatment success.2 In another survey
study, patients with rheumatoid arthritis who were considering anti-TNF therapy
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were equally receptive to both SC and IV agents.3 Results
derived from a treatment satisfaction questionnaire (TSQM
version II) indicated a high level of patient satisfaction with
either SC or IV administration.2 Progressive data indicate
that a shared decision-making process is important to the
successful outcomes of a new treatment plan.4,5 Thus, it is
reasonable that patient preferences for an SC or IV biologic
be explored to assess what is optimal for both the patient’s
and the rheumatologist’s treatment goals.
Few studies have addressed the positive or negative
attributes associated with specific modes of administration of biologic therapies for inflammatory arthropathies.
To address these issues, we developed a questionnaire to
explore patient perspectives regarding treatment with an
IV biologic. The primary objective was to obtain patientreported outcome (PRO) information that may be used
to better understand the treatment perceptions of patients
receiving IV biologics for IA.

Methods
Study design and patients
The PRO IV study was a single-center, noninterventional,
patient questionnaire-based study conducted over ~8 weeks
and enrolled adults with IA who were currently receiving
therapy with IV biologics. The protocol was approved by the
institutional review board for the site (Western Institutional
Review Board). Each patient completed one questionnaire at
a single infusion visit. There were no restrictions with respect
to the IV biologic used to treat patients’ IA.
Adults with a diagnosis of IA were eligible if they were
receiving IV biologic treatment for $3 months before
screening, had the ability to understand and sign an informed
consent form, were willing to complete a paper questionnaire, and could read, write, and speak English. Patients were
excluded if they had a serious concomitant illness that could
otherwise interfere with their ability to complete the questionnaire or if they were participating in any interventional
investigational clinical study. Patients were selected from one
site and informed that the study would not affect treatment.
Written informed consent was obtained from all patients at
a screening visit which occurred within 2 weeks before the
visit when the questionnaire was administered.

Questionnaire
The PRO IV questionnaire comprised 30 questions developed to characterize and quantify the patients’ experience
of receiving an IV therapy to treat their IA. The questionnaire included questions on patient demographics, disease
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characteristics for which they were receiving their current IV
biologic therapy, medical history, previous biologic treatment
for IA (including both self-administered SC and IV administrations), education level, insurance status, and whether
patients discussed IV therapy with health-care professionals
before receiving an IV therapy.
Patients were asked to rate their perception of IV biologic
treatment as recalled from before and after receiving treatment with IV therapy using a 5-point Likert scale (1= not
favorable, 5= extremely favorable). All patients were asked
to rate their agreement with statements regarding satisfaction with their current IV biologic therapy and potential
advantages and disadvantages of IV biologic therapy using
a 5-point Likert scale (1= strongly disagree, 2= disagree,
3= neutral, 4= agree, and 5= strongly agree). Patients who
had previously received an SC biologic therapy for their
IA were asked additional questions assessing the potential
reasons why they switched from SC to IV administration.
This subgroup of patients was presented with several possible
reasons for why they switched from an SC to an IV biologic
for their IA, and they were asked to rate their agreement with
the statements using the 5-point Likert scale (1= strongly
disagree, 5= strongly agree).
The questionnaire was administered at the study visit by
the study site coordinator. In all cases, the study visit was
a regularly scheduled infusion visit, and the questionnaire
was completed by the patient in a separate room before
the infusion.

Safety
This was an observational study that did not involve the
administration of any therapies to patients. There was no
proactive safety data collection component; incidental,
spontaneous reports of adverse events or serious adverse
events that were described by the patient, either in the patient
questionnaire or verbally to members of the clinical study
staff during the study, were to be reported. However, no
adverse events or other safety data were reported.

Statistical analysis
Version 3.2.1 of R and Statistical Analysis System version
9.2 were used for all analyses. Descriptive statistics summarized the questionnaire responses, means and SDs for
continuous variables and frequencies and percentages for
categorical variables. Bar charts were plotted for categorical
variables (eg, favorability ratings before and after IV treatment). Subgroup analyses were performed with patients
stratified by previous use of self-administered SC treatment
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(yes/no) to assess patient opinion on IV treatment before
and after receiving IV therapy and perceived advantages
and disadvantages of SC and IV treatments. McNemar’s
test was used to evaluate the changes in perception of IV
therapy before and after receiving treatment.

Results
Patient demographics and disease
characteristics
One hundred patients were enrolled, with a mean age of
58.35 years. Mean disease duration was 10.10 years; 68%
had rheumatoid arthritis, 21% had psoriatic arthritis, 9%
had ankylosing spondylitis, and 2% had Crohn’s disease/IA.
Patients were, on average, obese based on a mean body mass
index (BMI) of 30.29. The study population was ethnically
diverse. The most common comorbidity was hypertension
(44%). A total of 46% of patients reported graduating college or attending graduate school, and 43% graduated high
school or attended some college. Nearly half of all patients
were working full time (48%), with the next largest group
being retired or unemployed (43%). All but one patient (99%)
reported having health insurance (Medicare, Medicaid, or
Private), while 82% of patients also said they had a prescription plan (Table S1).
The majority of patients reported positive responses to
the lifestyle questions: 64% used daily vitamins, 57% used
additional supplements on a regular basis, 79% ate a balanced diet (including several servings of fruits and vegetables
daily), 85% tried to get $7 hours of sleep each night, and
61% had a busy/active lifestyle. Among all patients, 45%
reported exercising regularly ($3 times/week). A total of
69% of patients rated their health as 4 or 5 (1= very poor
health, 5= perfect health) during the previous month, and 7%
reported a health status of 1 or 2 (Table S1); the mean ± SD
health rating score was 3.86±0.93.

Current and previous biologic therapies
for inflammatory arthritis
Among biologics that patients had previously used for their
IA, the most commonly used class was anti-TNF agents
(infliximab, 20%; etanercept, 22%; adalimumab, 19%;
golimumab SC, 3%; golimumab IV, 1%). Patients also
reported previous treatment with abatacept (8%), tocilizumab (4%), rituximab (2%), and certolizumab (1%). A total
of 31% of patients had received SC biologic treatment before
starting an IV biologic.
Five IV biologics were reported as current therapies for
IA in this population: infliximab (71%), rituximab (12%),
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tocilizumab (10%), abatacept (6%), and golimumab (1%);
mean exposures for these therapies were 4.74, 2.94, 1.43,
3.44, and 0.42 (n=1) years, respectively. The overall mean
duration of IV therapy was 4.07 years (range: 0.08–16.00
years). Nearly all patients (97%) reported receiving counseling about their IV infusion therapy before initiating treatment;
of these, 97% reported counseling from a physician (part of
a shared decision-making experience), 37% from a nurse
or a nurse practitioner, 92% reported that they had received
pamphlets or other reading material in preparation for beginning their IV infusion therapy, and 12% reported that they
were directed to a website for information.

Perceptions of current intravenous
biologic therapy for inflammatory
arthritis
Seventy-seven percent of patients were very satisfied
(level 5) with using an IV infusion medication (Figure 1A),
and one patient (1%) indicated a rating of “not at all satisfied” (level 1). The overall mean ± SD level of satisfaction with all currently used IV infusion therapies was
4.63±0.79. On an individual therapy basis, mean scores were
4.76±0.60 for infliximab, 4.67±0.52 for abatacept, 4.00±1.41
for tocilizumab, 4.33±0.98 for rituximab, and 5.0 (n=1) for
golimumab.
Patients were asked to rate their level of agreement
(1= strongly disagree, 5= strongly agree) with statements
related to receiving IV therapy for IA. Patients had the highest mean scores for the statements “My doctor felt strongly
that an IV medication was the best choice for me,” “The
doctor can adjust the dose of medication if needed,” and
“I believe that IV medications are strong medications”
(Table 1). Thirty-one patients had previous experience with
self-administration of SC biologics. In general, there were
no apparent differences between patients with previous SC
biologic experience and those without previous SC biologic
experience in the relative rank of agreement with these statements (Table 1). However, when compared with patients
without prior SC injection experience, patients with prior
SC injection experience had a lower mean agreement score
in response to the statement “I would be concerned about the
risk of hurting or injuring myself if I had to give myself shots”
(4.20 vs 2.77, respectively). A similar trend was observed
in response to the statement “I don’t like needles and don’t
like the idea of having to give myself shots” (3.99 vs 3.13,
respectively) (Table 1).
Patients were queried in regard to their perception of IV
therapy to treat their IA before and after starting IV therapy.
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Figure 1 Actual question: How satisfied are you with using an IV infusion medication? Patient satisfaction with IV infusion therapy (A) and favorability of IV treatment before
and after initiating IV infusion therapy for all patients (B) and for patients with and without previous experience with SC agents (C).
Abbreviations: IV, intravenous; SC, subcutaneous.

Among all patients, 33% had an “extremely favorable”
perception of IV therapy before initiating their current IV
treatment, and this increased to 71% following initiation of
their current therapy (P,0.0001) (Figure 1B). Likewise,

the mean ± SD favorability perception score for IV therapy
increased from 3.73±1.21 to 4.54±0.87 after patients initiated
their current IV infusion therapy. The increase in favorability
among patients’ perception of their current IV therapy was

Table 1 Patient agreement with statements regarding use of current IV biologic therapy for IA (5-point scale: 1= strongly disagree,
5= strongly agree)
All patients
(n=100)

No previous
self-injection
(n=69)

Previous
self-injection
(n=31)

My doctor felt strongly that an IV medication was the best choice for me
The doctor can adjust the dose of medication if needed

4.55±0.67
4.49±0.82

4.51±0.72
4.51±0.78

4.65±0.55
4.45±0.93

I believe that IV medications are strong medications
For my lifestyle, it is easier for me to schedule an appointment at an
infusion center than to remember when to give myself shots
I believe an IV infusion would not be painful
Other medications did not control my symptoms
The infusion center is close to my home or office, making it convenient
I would be concerned about the risk of hurting or injuring myself if I had
to give myself shots
I don’t like needles and don’t like the idea of having to give myself shots
My co-pay or out-of-pocket cost is lower with an IV infusion medication
than medications that I would have to administer as shots

4.24±0.78
4.17±1.10

4.25±0.85
4.48±0.87

4.23±0.62
3.48±1.26

4.12±0.82
4.06±0.91
3.89±1.25
3.76±1.32

4.28±0.71
4.09±0.92
3.94±1.25
4.20±1.10

3.77±0.96
4.00±0.89
3.77±1.26
2.77±1.26

3.72±1.32
3.53±1.00

3.99±1.28
3.65±0.94

3.13±1.23
3.26±1.09

Note: Data presented as mean ± SD.
Abbreviations: IA, inflammatory arthritis; IV, intravenous.
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agreement with these choices is shown in Figure 2. These
patients agreed most strongly with the statement, “The
medication administered by shots wasn’t working” (mean
score ± SD: 4.03±1.08). Mean responses to the other reasons
presented to patients were generally “Neutral” (neutral =3,
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independent of whether they had previously received an SC
biologic for IA (Figure 1C).
Patients with prior SC biologic experience (n=31) were
presented with possible reasons for why they switched
from an SC to an IV biologic. The distribution of level of
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Figure 2 Level of patient agreement with reasons for switching from SC to IV therapy for IA: (A) The medication administered by shots wasn’t working. (B) I had side effects
to the medication administered by shots. (C) The cost of IV infusion medication was less. (D) I had difficulty remembering when to administer the shots. (E) I had difficulty
administering the shots. (F) I didn’t like giving myself shots.
Abbreviations: IA, inflammatory arthritis; IV, intravenous; SC, subcutaneous.
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patients tending to not agree or disagree): side effects from
SC medication (2.87), cost of IV medication (2.84), difficulty
remembering when to administer SC medication (3.03), difficulty administering SC medication (3.00), and not liking to
give SC injections to themselves (3.23).
Patients were presented with several possible advantages
and disadvantages of using IV biologics and asked to rate
how strongly they agreed (1= strongly disagree, 5= strongly
agree) with the statements (Table 2). Of the possible advantages, patients agreed most strongly with the statement “The
medication is being administered by professionals who can
monitor for any side effects” (mean ± SD score: 4.79±0.50).
Patient responses were neutral toward the potential advantages “Infusion therapy is less costly” (3.42±1.12) and “I take
advantage of other activities such as shopping or going out
to eat on days when I have to go to the infusion center”

(3.32±1.18). Mean scores for the potential disadvantages
that were presented to patients (eg, I have to travel to an
infusion facility center [2.79±1.31] and the duration of the
infusion itself takes too much time [2.47±1.15]) were all
below 3 (neutral). This indicates that from the perspective
of the patients, they did not strongly agree that the proposed
statements were in fact disadvantages. No outstanding
disadvantage to using IV biologics was identified by these
patients. There were no apparent differences in the responses
to either potential advantages or disadvantages between
patients who had previously used SC biologics and those
who had not (Figure 2).
All patients were asked to rate their level of agreement
with potential advantages and disadvantages of receiving
their IA medication by an SC injection (Table 3). All of the
statements describing the potential benefits of SC treatment

Table 2 Patient agreement with potential advantages and disadvantages to receiving IV infusion therapy for IA (5-point scale: 1= strongly
disagree, 5= strongly agree)

Potential advantages
The medication is being administered by professionals who can monitor for
any side effects
The staff at the infusion center keeps track of when I need my next dose of
medication and my next doctor’s appointment and keeps me on schedule
The staff of medical professionals can assess how I am doing
The visit for my infusion provides another assessment beyond my regular
doctor visit
I want to have a health-care professional administer the medication to me
Infusion therapy is more consistent with my lifestyle
With IV therapy, I don’t have to fear about injecting myself
I like being able to socialize with the staff and other patients at the infusion unit
The staff of medical professionals at the infusion center can also monitor my
other medical conditions
The infrequent dosing is an advantage
Infusion therapy is less costly
I take advantage of other activities such as shopping or going out to eat on
days when I have to go to the infusion center
Potential disadvantages
I have to travel to an infusion facility
The cost of the infusion, such as the co-insurance or co-pay costs
The infusion itself takes too much time
Frequent scheduling issues, such as time off work, finding a babysitter, etc
The cost of going to the infusion center, such as gas, parking, etc
Missing several hours from work or school
I don’t like seeing the IV needle
The loss of vacation days from work
The need for IV treatment reminds me that I am sick
I don’t like being in a setting with other people who may be very ill
The IV infusion is difficult since I have poor veins

All patients
(n=100)

No previous
self-injection
(n=69)

Previous
self-injection
(n=31)

4.79±0.50

4.77±0.52

4.84±0.45

4.69±0.61

4.67±0.68

4.74±0.44

4.68±0.57
4.45±0.70

4.67±0.59
4.36±0.75

4.71±0.53
4.65±0.55

4.44±0.81
4.21±0.99
4.20±1.03
4.15±0.90
4.13±0.96

4.55±0.74
4.39±0.84
4.48±0.87
4.22±0.91
4.16±0.93

4.19±0.91
3.81±1.17
3.58±1.12
4.00±0.89
4.06±1.03

4.09±0.90
3.42±1.12
3.32±1.18

4.22±0.81
3.58±1.12
3.39±1.24

3.80±1.03
3.06±1.06
3.16±1.04

2.79±1.31
2.55±1.22
2.47±1.15
2.30±1.16
2.26±1.14
2.23±1.12
2.22±1.12
2.15±1.09
2.15±1.15
1.97±0.95
1.92±1.08

2.74±1.29
2.57±1.23
2.46±1.17
2.33±1.18
2.22±1.15
2.32±1.13
2.26±1.17
2.23±1.11
2.13±1.16
1.97±1.00
1.94±1.11

2.90±1.37
2.52±1.21
2.48±1.12
2.23±1.12
2.35±1.14
2.03±1.08
2.13±0.99
1.97±1.02
2.19±1.14
1.97±0.84
1.87±1.02

Note: Data presented as mean ± SD.
Abbreviations: IA, inflammatory arthritis; IV, intravenous.
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Table 3 Patient agreement with potential advantages and disadvantages of self-administration of SC therapy for IA (5-point scale:
1= strongly disagree, 5= strongly agree)

Potential advantages
I could avoid a trip to the doctor’s office
I would use less health-care resources
Injections (shots) are less costly for me
I have more control of when I take my medicine
I am comfortable giving myself shots
I feel I am in more control of my disease
I can remember to give myself shots vs remembering an appointment
I don’t want to be around others when getting a medical treatment
Potential disadvantages
There is no medical staff immediately available if I experience side effects
from the medication
I would worry about the refrigeration, keeping refrigerated while traveling,
ordering the medication from the pharmacy, etc
I am not comfortable injecting myself
The doctor may not be able to adjust the dose of medication with the shot
I would worry about disposing of the needles
I need to remember when to give myself shots
I would worry about having needles in the house (potential danger to
children and pets)
There is no opportunity for socialization, such as talking with the staff or
other patients with my condition
My out-of-pocket costs might be higher (co-pay, co-insurance)
I have too many other medical conditions to take care of already

All patients
(n=100)

No previous
self-injection
(n=69)

Previous
self-injection
(n=31)

2.68±1.25
2.63±0.99
2.60±0.95
2.36±1.14
2.33±1.33
2.26±1.19
2.25±1.13
2.03±0.95

2.67±1.30
2.62±0.99
2.56±0.98
2.32±1.19
2.14±1.36
2.17±1.24
2.13±1.17
1.99±0.98

2.71±1.16
2.65±1.02
2.68±0.87
2.45±1.03
2.74±1.18
2.45±1.09
2.52±1.00
2.13±0.88

4.08±1.10

4.10±1.18

4.03±0.91

3.89±1.19

3.91±1.27

3.84±1.00

3.88±1.16
3.85±1.07
3.71±1.23
3.70±1.21
3.55±1.26

4.09±1.15
3.87±1.16
3.80±1.26
3.59±1.33
3.67±1.29

3.42±1.06
3.81±0.87
3.52±1.15
3.94±0.85
3.29±1.16

3.50±1.17

3.55±1.23

3.39±1.02

3.27±1.01
3.29±1.18

3.32±1.03
3.30±1.28

3.16±0.97
3.26±0.96

Note: Data presented as mean ± SD.
Abbreviations: IA, inflammatory arthritis; SC, subcutaneous.

received mean scores ,3 (neutral). The opposite was
observed for statements regarding potential disadvantages
of receiving their medication as an SC injection, with mean
scores .3. Patients agreed most strongly with the potential
disadvantage statement of “There is no medical staff
immediately available if I experience side effects from the
medication” (mean ± SD disadvantage score: 4.08±1.10).
Mean patient responses to the potential disadvantages and
advantages of receiving treatment as an SC injection were

similar whether the patients had previous experience with
self-injection (Table 3).
Thirty-nine patients reported that they had to take time
off from work to receive their IV infusion. The majority of
these patients agreed or strongly agreed that it was not a
problem to miss time from work to receive their infusion; few
patients agreed with statements indicating difficulties with
missing time from work to receive their infusions (Table 4).
Sixty-one percent of all patients reported that travel time to

Table 4 Patient agreement with statements regarding difficulty missing time from work, among those who miss time from work to
receive infusions for IA (n=39)

How difficult is it to get the time off from work, n (%)
Not a problem – the company (or supervisor) is very understanding
Not a problem – I make up the time later in the week
Slight problem – I always have to negotiate when I can leave and when
the time will be made up
It’s a problem – I need to sneak out early or call in sick to make the visit
It’s a problem since I don’t get paid for the time I miss at work

Strongly
agree

Agree

Neutral

Disagree

Strongly
disagree

21 (53.8)
15 (38.5)
2 (5.1)

13 (33.3)
7 (17.9)
2 (5.1)

5 (12.8)
11 (28.2)
10 (25.6)

−
3 (7.7)
10 (25.6)

−
3 (7.7)
15 (38.5)

1 (2.6)
2 (5.1)

1 (2.6)
4 (10.3)

10 (25.6)
8 (20.5)

9 (23.1)
9 (23.1)

18 (46.2)
16 (41.0)

Note: Data presented as n (%).
Abbreviation: IA, inflammatory arthritis.
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the infusion center was ,30 minutes, while 36% reported
travel time between 31 and 60 minutes, and 3% of patients
reported that their travel time was .60 minutes. Mean agreement scores (1= strongly disagree, 5= strongly agree) for the
statements “Not a problem; my company or supervisor is
understanding” and “Not a problem; I make up the time later
in the week” were 4.41±0.72 and 3.72±1.28, respectively,
indicating agreement; whereas, mean agreement scores for
the statements “It’s a problem; I need to sneak out early or
call in sick to make the visit” and “It’s a problem; I don’t
get paid for the time I miss at work” were 1.92±1.04 and
2.15±1.23, respectively, indicating less agreement by the
patients with these statements.

Discussion
There are a variety of factors that influence a patient’s decision in regards to choosing therapy for their IA. Among
the available choices are biologic drugs administered either
as an SC injection or IV infusion. A key component in the
decision-making process is the patient–physician relationship. It is increasingly evident that the physician should
discuss the advantages and disadvantages of each treatment
option with the patient.5–7 As the results of this study indicate,
some patients may perceive meaningful differences between
treatment modalities. Other patients may identify advantages
with a certain route of administration based on individual
preferences and perceptions. The results presented here
support a shared decision-making process between the patient
and the physician, in which the patient is offered the available
options in sufficient detail, and then the patient’s perception
and preference for treatment options are highly considered.
In this study of 100 patients currently receiving IV
therapy for IA, there was a high level of satisfaction
among all patients with regard to their experience with IVadministered biologic therapy. A total of 90% of patients
ranked their satisfaction with IV therapy as 4 or 5, with 77%
ranking satisfaction as 5 (very satisfied). These results align
with a recent publication in which 82% of patients receiving
an IV biologic to treat an autoimmune disease (ie, ankylosing
spondylitis, rheumatoid arthritis, psoriatic arthritis, psoriasis,
Crohn’s disease, or ulcerative colitis) indicated a preference
for an IV-administered treatment over an SC-administered
treatment.8 In our study, overall, the decision to use IV
therapy was influenced primarily by the patients’ perception
of efficacy and the opinion of their treating physician. Patients
also tended to strongly agree with the statement that it was
easier to schedule appointments for their infusions rather than
remember to self-administer SC injections. Among patients
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who switched from an SC therapy to an IV therapy, the
primary reason for switching (among those in the questionnaire presented to the patient) pertained to efficacy. A total
of 67.8% of patients either agreed or strongly agreed that
the switch to IV infusion was related to the SC medication
“not working”. The reason for switching with the next highest level of agreement (agreed or strongly agreed) was that
patients did not like giving themselves SC injections (38.7%).
Among other possible reasons, the majority of patients were
neutral, disagreed, or strongly disagreed regarding adverse
events (80.7%), lower cost of IV medication (93.6%), difficulty remembering when to administer SC injections (77.4%),
or difficulty administering the SC injection (67.7%) as the
rationale for switching from SC to IV.
There was no apparent difference in the degree of
favorability reported for receiving IV therapy between
the patients who had previously used SC biologic therapy
and those who had not received prior SC therapy. Overall,
patients who had previously received SC therapy and later
switched to IV therapy identified multiple benefits of infusion therapy which were not available to them while they
were self-injecting. Although the differences were not
statistically significant, it is interesting to note that the four
“advantage” statements with the highest agreement scores
overall (among all patients) had even higher agreement scores
among patients with prior SC injection experience. Overall,
these highest-ranking potential advantages of IV treatment
suggest that constant professional reinforcement of disease
management, readily available health-care resources to assist
with any problem, and relationships developed with the staff
are meaningful to patients receiving IV biologic treatment.
These factors should be discussed as part of the shared
decision-making process.
Patients in our study had a more favorable perception
of IV therapy after receiving this therapy compared with
their recollection of how they felt about it before receiving
IV therapy. This relative shift in perception was observed
for both patients who had, and those who had not, received
SC biologic therapy previously. Regarding their use of
IV medication, reasons with the greatest agreement score
pertained to physician input on what the best therapy was
for the patients and that the physician would be able to
adjust the dose of medication as needed. These reasons
were the highest ranking independent of prior SC injection
experience. Similarly, among the potential advantages of
IV therapy, the highest-ranking factor pertained to the level
of health care provided as a component of the IV infusion
experience. Again, highest-ranking potential advantages
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were independent of prior SC injection experience. These
results suggest that patients had improved control of their
disease after receiving IV therapy and may have developed
a relationship with the infusion provider. Likewise, patients
may have bonded with the nurses, medical assistants, and/or
physicians at the site where this study was conducted. It was
observed that the average time patients had received their IV
therapy was .4 years, supporting the potential of a relationship-building aspect. Finding the time to have a monthly,
bi-monthly, or every-6-month infusion did not appear to be
a problem for the majority of patients. The need to schedule
the time off, either professionally or personally, seemed to
be an acceptable part of the infusion treatment plan. In some
instances, patients reported a level of positivity toward being
able to take a break from a schedule of normal life activities
to come in for an infusion where all of the work was done by
the staff and the experience was favorable. Of note, nearly all
patients reported having been educated about their IV infusion before starting treatment. Most of these patients (97%)
reported receiving consultation from a physician; 37% also
spoke with a nurse or a nurse practitioner. A survey of Belgian
patients with rheumatoid arthritis and rheumatologists (the
Be-Raise study) demonstrated that patients’ primary concerns
were centered on effectiveness of treatment.9 There was a
notable difference in the patient-reported satisfaction with
IV therapy (52.4%) and the perceived patient satisfaction
reported by physicians (29.9%).9 These results also support
a shared decision-making conversation with effective discussions between health care professionals and patients before
initiating therapy being a critical component of the shared
decision-making process regarding drug therapy choices.
The relative importance of patient perspective in treatment preferences of IA has also been assessed in a younger
population. In a study of patients aged 16–25 years who were
diagnosed with a spectrum of IA diseases, it was determined
that leading a “normal” life was an important overall goal
from the patients’ perspective.10 Hart et al also found that
young patients need active encouragement to discuss their
treatment concerns and difficulties with the care team,10 a
conclusion that coincides with our findings that support a
shared decision-making approach.
This study was conducted at a single site, which may limit
the generalizability of the results. For example, only 38%
of the population was reported as Caucasian and 28% were
reported as African American. This distribution is different
from a broader US-based IA population.11 Furthermore,
some of the items in the questionnaire relied on the patients’
recall of their prior perceptions and experiences. Patients also
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tended to have positive perceptions of their current health
status with IV therapy (majority rating of 4 or 5, with 5 being
perfect health), possibly suggesting an overall positive attitude toward IV infusion therapy. Despite these limitations,
our results demonstrate the characteristics and perceptions
of patients with IA receiving ongoing IV therapy.
Overall, the 100 patients who had received infusion
therapy for $3 months for their IA had a positive perception
regarding IV therapy. Of note, patients previously treated
with SC therapy had a similar positive perception. This
would suggest that physicians should strongly consider that
patients may be open and amenable to an infusion therapy
option as part of a shared decision discussion. Furthermore,
this illustrates the value of an outpatient infusion center where
there are experts, a consistent and knowledgeable staff, and
a comfortable environment which may be desirable and
beneficial to patients.
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Table S1 Baseline demographic and disease characteristics
Demographics

Patients (n=100)

Disease characteristics

Patients (n=100)

Age, years
Female
Weight, kg
BMI, kg/m2
Race
Caucasian
African American
Latino/Hispanic
Asian/Pacific Islander
Not identified
Education
Grade school
Some high school
High school graduate
Some college
College graduate
Graduate school
Trade school
Employment status
Full-time job
Part-time job
Student
Homemaker
Retired/unemployed
Health insurance
Medicare
Medicaid
Private

58.35±14.64
66
85.03±19.69
30.29±5.98

Disease duration, years
Disease duration range, years
Disease diagnosis
Rheumatoid arthritis
Ankylosing spondylitis
Psoriatic arthritis
Crohn’s disease/IA
Medical history
Heart disease
Congestive heart failure
Hypertension
Insulin-dependent diabetes
Non-insulin-dependent diabetes
Stroke
Peripheral vascular disease
Skin cancer
Cancer
Hepatitis
Tuberculosis
Chronic infection
Stomach/Duodenal ulcer
COPD/Emphysema
Current health scorea
1
2
3
4
5

10.10±8.14
0.67–45.00

38
28
22
1
11
3
3
19
24
29
17
5
48
7
1
1
43
39
7
72

68
9
21
2
7
1
44
4
11
2
5
8
5
3
0
3
9
5
2
5
24
43
26

Notes: Data presented as n or mean ± SD. aPatients were asked: “On a scale of 1–5, how would you rate your health over the past month?” 1= Very poor health, 5= Perfect
health.
Abbreviations: BMI, body mass index; COPD, Chronic Obstructive Pulmonary Disease; IA, inflammatory arthritis.
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